Loading...
Arovella Therapeutics Limited
ALA.AX•ASX
Healthcare
Biotechnology
A$0.10
A$0.006(6.06%)
Arovella Therapeutics Limited (ALA.AX) Financial Performance & Income Statement Overview
Review Arovella Therapeutics Limited’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
-95.81%
↓ 95.81%
Operating Income Growth
-11.68%
↓ 11.68%
Net Income Growth
14.10%
↑ 14.10%
Operating Cash Flow Growth
-8.07%
↓ 8.07%
Operating Margin
-140.39%
↓ 140.39%
Gross Margin
99.42%
↑ 99.42%
Net Profit Margin
-181.62%
↓ 181.62%
ROE
-55.00%
↓ 55.004%
ROIC
-41.87%
↓ 41.87%
Arovella Therapeutics Limited (ALA.AX) Income Statement & Financial Overview
Review Arovella Therapeutics Limited's (ALA.AX) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $4250.00 | $4250.00 | $8500.00 | $971811.00 |
| Cost of Revenue | $20162.00 | $0.00 | $1.47M | $0.00 |
| Gross Profit | -$15912.00 | $4250.00 | -$1.46M | $971811.00 |
| Gross Profit Ratio | -$3.74 | $1.00 | -$172.21 | $1.00 |
| R&D Expenses | $1.54M | $1.54M | $3.66M | $1.83M |
| SG&A Expenses | $480200.00 | $480200.00 | $835582.00 | $724722.00 |
| Operating Expenses | $2.02M | $2.02M | $4.49M | $2.98M |
| Total Costs & Expenses | $2.02M | $2.02M | $5.97M | $2.98M |
| Interest Income | $52532.00 | $0.00 | $86203.00 | $38786.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $20162.00 | $10081.00 | $22817.00 | $11409.00 |
| EBITDA | -$2.42M | -$2.42M | -$5.86M | -$2.000M |
| EBITDA Ratio | -$568.55 | -$568.55 | -$698.31 | -$2.06 |
| Operating Income | -$2.01M | -$2.01M | -$5.96M | -$2.01M |
| Operating Income Ratio | -$473.89 | -$473.89 | -$701.00 | -$2.07 |
| Other Income/Expenses (Net) | -$386082.00 | -$386082.00 | $77572.00 | $38786.00 |
| Income Before Tax | -$2.40M | -$2.40M | -$5.88M | -$1.97M |
| Income Before Tax Ratio | -$564.74 | -$564.74 | -$691.87 | -$2.03 |
| Income Tax Expense | $0.00 | -$412348.00 | -$1.94M | $0.00 |
| Net Income | -$2.40M | -$2.40M | -$3.95M | -$1.97M |
| Net Income Ratio | -$564.74 | -$564.74 | -$464.21 | -$2.03 |
| EPS | -$0.002 | -$0.002 | -$0.004 | -$0.002 |
| Diluted EPS | -$0.002 | -$0.002 | -$0.004 | -$0.002 |
| Weighted Avg Shares Outstanding | $982.45M | $982.45M | $900.51M | $896.77M |
| Weighted Avg Shares Outstanding (Diluted) | $982.33M | $982.33M | $900.51M | $900.51M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan